NateraCore Oncology | Natera

IN THE NEWS

Natera has announced that Signatera has been awarded Medicare coverage.

PRODUCT SPOTLIGHT

In 2019, Natera’s Signatera received an FDA Breakthrough Device designation.


YOUR SUPPORT RESOURCE

Our Oncology services give you the support you need to easily assimilate Signatera into your MRD assessment and surveillance workflows. Discover the tailored resources of NateraCore—accessible anytime, anyplace, so you can focus on patients.



Support every step of the way

We help testing fit seamlessly into your workflow via a flexible selection of tools and services for every point in a patient’s journey.

 


PRODUCT SPOTLIGHT

See up close how Signatera works, and learn how the first tumor-specific assay may help you make more informed treatment decisions and detect recurrence earlier.

Watch now


IN THE NEWS

Natera has announced exciting new data at ASCO, highlighting the utility of personalized MRD monitoring.

Read more